On March 25, 2026, Kyorin Pharmaceutical concluded an exclusive sales agreement in Japan for the tuberculosis chemotherapy drug ‘Satchuro\u00ae Tablets’ with Johnson & Johnson, planning to start sole promotion from June 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"Kyorin Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-03-25","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4569-20260325-01.pdf","jir_short_summary":"On March 25, 2026, Kyorin Pharmaceutical concluded an exclusive sales agreement in Japan for the tuberculosis chemotherapy drug 'Satchuro\u00ae Tablets' with Johnson & Johnson, planning to start sole promotion from June 2026.","jir_summary":"### Overview of the Agreement\nKyorin Pharmaceutical concluded an exclusive sales agreement in Japan for 'Satchuro\u00ae Tablets 100mg', a tuberculosis chemotherapy drug with Johnson & Johnson (J&J) on March 25, 2026. Satchuro\u00ae Tablets are used as combination therapy for multidrug-resistant pulmonary tuberculosis and are currently marketed by J&J. Kyorin Pharmaceutical plans to begin sole promotional activities from June 2026 and will procure products from J&J for exclusive sales following additional approval for pulmonary MAC disease indications.\n\n### Future Outlook and Impact\nThis agreement aligns with Kyorin Pharmaceutical\u2019s medium-term management plan 'Vision 110 \u2013 Stage1 \u2013' focusing on acquiring introduced products and is part of a franchise customer strategy targeting specialized fields such as pulmonology, otolaryngology, and urology. Aiming to contribute to the treatment of infectious disease patients, the impact on consolidated earnings guidance for the fiscal year ending March 2026 is expected to be minimal. There are no capital, personnel, or transactional relationships with J&J.","jir_financial_highlights":"Impact on Consolidated Earnings Guidance for Fiscal Year Ending March 2026: Minimal (Unknown)","jir_category":"","jir_hashtags":"#KyorinPharmaceutical, #M&A, #JapaneseStocks","jir_key_figures":"Agreement Date: March 25, 2026\nPlanned Promotion Start: June 2026\nImpact on Consolidated Earnings Guidance for Fiscal Year Ending March 2026: Minimal","jir_meta_title":"Kyorin Pharmaceutical Concludes Exclusive Sales Agreement for Tuberculosis Drug 'Satchuro\u00ae Tablets' in Japan, Starting Sales from June 2026","jir_meta_description":"Kyorin Pharmaceutical has entered into an exclusive sales agreement with Johnson & Johnson for the tuberculosis chemotherapy drug 'Satchuro\u00ae Tablets' in Japan. Sole promotion is scheduled to start in June 2026, with minimal expected impact on earnings.","jir_og_title":"Kyorin Pharmaceutical Concludes Exclusive Sales Agreement for Tuberculosis Drug 'Satchuro\u00ae Tablets' in Japan","jir_og_description":"Kyorin Pharmaceutical has signed an exclusive sales contract with Johnson & Johnson for 'Satchuro\u00ae Tablets', a tuberculosis chemotherapy drug, with sales planned to begin from June 2026.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-36609","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n